Use of atypical antipsychotics for treatment-resistant major depressive disorder

被引：4

作者：

Papakostas G.I. ^{[1
]}

Shelton R.C. ^{[1
]}

机构：

[1] Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114

来源：

Current Psychiatry Reports | 2008年 / 10卷 / 6期

关键词：

Risperidone; Olanzapine; Quetiapine; Venlafaxine; Major Depressive Disorder;

D O I：

10.1007/s11920-008-0077-3

中图分类号：

学科分类号：

摘要：

Despite the progressive increase in the number of pharmacologic agents with potential antidepressant activity, many patients suffering from major depressive disorder (MDD) continue to be symptomatic. Clearly, an urgent need exists to develop safer, better tolerated, and more effective treatments for MDD. Use of atypical antipsychotic agents as adjunctive treatment for treatment-resistant MDD (TRD) represents one such effort toward novel pharmacotherapy development. Atypical antipsychotic agents have been hypothesized to be beneficial in treating mood disorders, including TRD, as a result of their complex mechanisms of action. After an initial series of positive case reports, series, and small clinical trials, subsequent larger-scale projects have yielded conflicting results. However, more recently, larger-scale clinical trials have supported the effectiveness of at least some of these medications. This review summarizes the existing data regarding the effectiveness of these medications in treating TRD, including biochemical rationale and clinical data. © Current Medicine Group LLC 2008.

引用

页码：481 / 486

页数：5

共 53 条

[1]

Trivedi M.H., Rush A.J., Wisniewski S.R., Et al., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice, Am J Psychiatry, 163, pp. 28-40, (2006)

[2]

Petersen T., Papakostas G.I., Posternak M.A., Et al., Empirical testing of two models for staging antidepressant treatment resistance, J Clin Psychopharmacol, 25, pp. 336-341, (2005)

[3]

Papakostas G.I., Petersen T., Denninger J.W., Et al., Psychosocial functioning during the treatment of major depressive disorder with fluoxetine, J Clin Psychopharmacol, 24, pp. 507-511, (2004)

[4]

Paykel E.S., Ramana R., Cooper Z., Et al., Residual symptoms after partial remission: An important outcome in depression, Psychol Med, 25, pp. 1171-1180, (1995)

[5]

Thase M.E., Friedman E.S., Biggs M.M., Et al., Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: A STAR*D report, Am J Psychiatry, 164, pp. 739-752, (2007)

[6]

Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis, Lancet, 361, pp. 799-808, (2003)

[7]

Rush A.J., Marangell L.B., Sackeim H.A., Et al., Vagus nerve stimulation for treatment-resistant depression: A randomized, controlled acute phase trial, Biol Psychiatry, 58, pp. 347-354, (2005)

[8]

O'Reardon J.P., Solvason H.B., Janicak P.G., Et al., Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial, Biol Psychiatry, 62, pp. 1208-1216, (2007)

[9]

Fava M., Alpert J., Nierenberg A., Et al., Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine, J Clin Psychopharmacol, 22, pp. 379-387, (2002)

[10]

Papakostas G.I., Fava M., Thase M.E., Treatment of SSRI-resistant depression: A meta-analysis comparing within-versus across-class switches, Biol Psychiatry, 63, pp. 699-704, (2008)

← 1 2 3 4 5 6 →